Aura Biosciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Elisabet de los Pinos
- Full Time Employees
- 106
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 85 Bolton Street Boston MA United States of America 02140
- IPO Date
- Oct 29, 2021
- CIK
- 0001501796
- Website
- aurabiosciences.com
- Similar Companies
- Business
- Aura Biosciences, Inc. engages primarily in the development and commercialization of targeted oncology therapeutics. The company specializes in the design, manufacture, and clinical development of tumor-specific therapeutics including nanopharmaceuticals, protein-engineered biologics, and antibody-drug conjugates. Its main product offerings include lead candidates such as AU-011, a proprietary virus-like drug conjugate targeting ocular melanoma and other solid tumors, as well as other immuno-oncology and antiviral therapies. Aura Biosciences primarily operates in the United States, with its headquarters located in Boston, Massachusetts. Founded in 2015, the company focuses on leveraging its proprietary Illuminox platform to develop innovative medicines that selectively target cancer cells. In the past 1-2 years, Aura Biosciences has made significant strides including advancing its clinical trials for AU-011 and expanding its pipeline with new product candidates. The company also completed a recent public funding round to support late-stage clinical development and strategic partnerships to enhance its research capabilities and commercialization efforts. There were no reports of name changes or reorganizations, but operational focus has shifted toward broader clinical indications and potential geographic market expansions beyond North America. Aura continues to position itself as a clinical-stage biopharmaceutical company focused on precision oncology treatments. Overall, Aura Biosciences operates within the biotechnology and pharmaceutical sectors, serving global oncology patient markets through innovative therapeutic product development. It maintains research and development operations in the U.S. and collaborates extensively with academic and industry partners to drive therapeutic innovation and commercialization. This description presents Aura Biosciences as a clinical-stage biotech company focused on targeted cancer therapies, emphasizing its products, recent clinical and funding developments, and operational footprint to align with financial data provider standards.
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
AMG Reports Better than Expected First Quarter 2026 Results
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of “Hold” by Brokerages
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?